Global Retinoblastoma Treatment Outcomes: Association with National Income Level.


Journal

Ophthalmology
ISSN: 1549-4713
Titre abrégé: Ophthalmology
Pays: United States
ID NLM: 7802443

Informations de publication

Date de publication:
05 2021
Historique:
received: 28 07 2020
revised: 17 09 2020
accepted: 21 09 2020
pubmed: 3 10 2020
medline: 9 10 2021
entrez: 2 10 2020
Statut: ppublish

Résumé

To compare metastasis-related mortality, local treatment failure, and globe salvage after retinoblastoma in countries with different national income levels. International, multicenter, registry-based retrospective case series. Two thousand one hundred ninety patients, 18 ophthalmic oncology centers, and 13 countries on 6 continents. Multicenter registry-based data were pooled from retinoblastoma patients enrolled between January 2001 and December 2013. Adequate data to allow American Joint Committee on Cancer staging, eighth edition, and analysis for the main outcome measures were available for 2085 patients. Each country was classified by national income level, as defined by the 2017 United Nations World Population Prospects, and included high-income countries (HICs), upper middle-income countries (UMICs), and lower middle-income countries (LMICs). Patient survival was estimated with the Kaplan-Meier method. Logistic and Cox proportional hazards regression models were used to determine associations between national income and treatment outcomes. Metastasis-related mortality and local treatment failure (defined as use of secondary enucleation or external beam radiation therapy). Most (60%) study patients resided in UMICs and LMICs. The global median age at diagnosis was 17.0 months and higher in UMICs (20.0 months) and LMICs (20.0 months) than HICs (14.0 months; P < 0.001). Patients in UMICs and LMICs reported higher rates of disease-specific metastasis-related mortality and local treatment failure. As compared with HICs, metastasis-related mortality was 10.3-fold higher for UMICs and 9.3-fold higher for LMICs, and the risk for local treatment failure was 2.2-fold and 1.6-fold higher, respectively (all P < 0.001). This international, multicenter, registry-based analysis of retinoblastoma management revealed that lower national income levels were associated with significantly higher rates of metastasis-related mortality, local treatment failure, and lower globe salvage.

Identifiants

pubmed: 33007338
pii: S0161-6420(20)30957-X
doi: 10.1016/j.ophtha.2020.09.032
pii:
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

740-753

Informations de copyright

Copyright © 2020 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.

Auteurs

Ankit Singh Tomar (AS)

Department of Ocular Tumor and Orbital Disease, The New York Eye Cancer Center, New York, New York.

Paul T Finger (PT)

Department of Ocular Tumor and Orbital Disease, The New York Eye Cancer Center, New York, New York. Electronic address: pfinger@eyecancer.com.

Brenda Gallie (B)

The Eye Cancer Clinic, Princess Margaret Cancer Centre, Toronto, Canada.

Tero T Kivelä (TT)

Ocular Oncology Service, Department of Ophthalmology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.

Ashwin Mallipatna (A)

Department of Ophthalmology and Vision Sciences, Hospital for Sick Children, Toronto, Canada.

Chengyue Zhang (C)

Pediatric Oncology Center, Beijing Children's Hospital, Beijing, China.

Junyang Zhao (J)

Pediatric Oncology Center, Beijing Children's Hospital, Beijing, China.

Matthew W Wilson (MW)

Department of Ophthalmology, Hamilton Eye Institute, University of Tennessee Health Science Center, College of Medicine, and Department of Surgery, St. Jude Children's Research Hospital, Memphis, Tennessee.

Rachel C Brenna (RC)

Department of Ophthalmology, Hamilton Eye Institute, University of Tennessee Health Science Center, College of Medicine, and Department of Surgery, St. Jude Children's Research Hospital, Memphis, Tennessee.

Michala Burges (M)

Department of Ophthalmology, Hamilton Eye Institute, University of Tennessee Health Science Center, College of Medicine, and Department of Surgery, St. Jude Children's Research Hospital, Memphis, Tennessee.

Jonathan Kim (J)

USC Roski Eye Institute, Keck Medical School of the University of Southern California, and The Vision Center at Children's Hospital Los Angeles, Los Angeles, California.

Vikas Khetan (V)

Department of Vitreoretina Services, Sankara Nethralaya, Chennai, Tamil Nadu, India.

Suganeswari Ganesan (S)

Department of Vitreoretina Services, Sankara Nethralaya, Chennai, Tamil Nadu, India.

Andrey Yarovoy (A)

Department of Ocular Oncology, The S. N. Fyodorov Eye Microsurgery Federal State Institution, Moscow, Russia.

Vera Yarovaya (V)

Department of Ocular Oncology, The S. N. Fyodorov Eye Microsurgery Federal State Institution, Moscow, Russia.

Elena Kotova (E)

Department of Ocular Oncology, The S. N. Fyodorov Eye Microsurgery Federal State Institution, Moscow, Russia.

Yacoub A Yousef (YA)

Department of Surgery (Ophthalmology), King Hussein Cancer Center, Amman, Jordan.

Kalle Nummi (K)

Ocular Oncology Service, Department of Ophthalmology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.

Tatiana L Ushakova (TL)

SRI of Pediatric Oncology and Hematology, N. N. Blokhin National Medical Research Center Oncology of Russian Federation, Moscow, Russia; Medical Academy of Postgraduate Education, Moscow, Russia.

Olga V Yugay (OV)

SRI of Pediatric Oncology and Hematology, N. N. Blokhin National Medical Research Center Oncology of Russian Federation, Moscow, Russia.

Vladimir G Polyakov (VG)

SRI of Pediatric Oncology and Hematology, N. N. Blokhin National Medical Research Center Oncology of Russian Federation, Moscow, Russia; Medical Academy of Postgraduate Education, Moscow, Russia.

Marco A Ramirez-Ortiz (MA)

Department of Ophthalmology, Hospital Infantil de México Federico Gómez, Mexico City, Mexico.

Elizabeth Esparza-Aguiar (E)

Department of Ophthalmology, Hospital Infantil de México Federico Gómez, Mexico City, Mexico.

Guillermo Chantada (G)

Precision Medicine Coordination Hospital J. P. Garrahan, and CONICET (National Scientific and Technical Research Council), Buenos Aires, Argentina.

Paula Schaiquevich (P)

Precision Medicine Coordination Hospital J. P. Garrahan, and CONICET (National Scientific and Technical Research Council), Buenos Aires, Argentina.

Adriana Fandino (A)

Ophthalmology Service, Hospital J. P. Garrahan, Buenos Aires, Argentina.

Jason C Yam (JC)

Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Kowloon, Hong Kong.

Winnie W Lau (WW)

Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Kowloon, Hong Kong.

Carol P Lam (CP)

Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Kowloon, Hong Kong.

Phillipa Sharwood (P)

Save Sight Institute, Discipline of Ophthalmology, Sydney Medical School, University of Sydney, Sydney, Australia.

Sonia Moorthy (S)

K. K. Women's and Children's Hospital, Singapore, Republic of Singapore.

Quah Boon Long (QB)

K. K. Women's and Children's Hospital, Singapore, Republic of Singapore.

Vera Adobea Essuman (VA)

Ophthalmology Unit, Department of Surgery, School of Medicine and Dentistry, College of Health Sciences, University of Ghana, Accra, Ghana.

Lorna A Renner (LA)

Department of Child Health, University of Ghana Medical School, Accra, Ghana.

Ekaterina Semenova (E)

Department of Ocular Tumor and Orbital Disease, The New York Eye Cancer Center, New York, New York.

Jaume Català (J)

Retinoblastoma Unit, Department of Ophthalmology, Hospital Sant Joan de Déu. Esplugues de Llobregat, Barcelona, Spain.

Genoveva Correa-Llano (G)

Retinoblastoma Unit, Department of Oncology, Hospital Sant Joan de Déu. Esplugues de Llobregat, Barcelona, Spain.

Elisa Carreras (E)

Retinoblastoma Unit, Department of Oncology, Hospital Sant Joan de Déu. Esplugues de Llobregat, Barcelona, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH